Cargando…
DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883251/ https://www.ncbi.nlm.nih.gov/pubmed/36707503 http://dx.doi.org/10.1038/s41408-022-00781-8 |
| _version_ | 1784879468586729472 |
|---|---|
| author | Kost, Sara E. F. Saleh, Ali Yuan, Shek H. Kuzio, Bozena Gibson, Spencer B. Yang, Lin Banerji, Versha Johnston, James B. Katyal, Sachin |
| author_facet | Kost, Sara E. F. Saleh, Ali Yuan, Shek H. Kuzio, Bozena Gibson, Spencer B. Yang, Lin Banerji, Versha Johnston, James B. Katyal, Sachin |
| author_sort | Kost, Sara E. F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9883251 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98832512023-01-29 DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease Kost, Sara E. F. Saleh, Ali Yuan, Shek H. Kuzio, Bozena Gibson, Spencer B. Yang, Lin Banerji, Versha Johnston, James B. Katyal, Sachin Blood Cancer J Correspondence Nature Publishing Group UK 2023-01-27 /pmc/articles/PMC9883251/ /pubmed/36707503 http://dx.doi.org/10.1038/s41408-022-00781-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Kost, Sara E. F. Saleh, Ali Yuan, Shek H. Kuzio, Bozena Gibson, Spencer B. Yang, Lin Banerji, Versha Johnston, James B. Katyal, Sachin DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease |
| title | DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease |
| title_full | DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease |
| title_fullStr | DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease |
| title_full_unstemmed | DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease |
| title_short | DNA-PK hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease |
| title_sort | dna-pk hyperactivation occurs in deletion 11q chronic lymphocytic leukemia and is both a biomarker and therapeutic target for drug-resistant disease |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883251/ https://www.ncbi.nlm.nih.gov/pubmed/36707503 http://dx.doi.org/10.1038/s41408-022-00781-8 |
| work_keys_str_mv | AT kostsaraef dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease AT salehali dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease AT yuanshekh dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease AT kuziobozena dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease AT gibsonspencerb dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease AT yanglin dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease AT banerjiversha dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease AT johnstonjamesb dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease AT katyalsachin dnapkhyperactivationoccursindeletion11qchroniclymphocyticleukemiaandisbothabiomarkerandtherapeutictargetfordrugresistantdisease |